Health AI Central
Share:
Peer-Reviewed Publication
Wiad Lek2025;78(10):1941-1950.January 1, 2025Journal Article

Hepatoprotective role of vildagliptin in CLP-induced sepsis in mice.

Adhwaa M Al-Shimary1, Ali M Janabi2, Carsten Ehrhardt3
1BABYLON HEALTH DIRECTORATE, BABYLON, IRAQ.
2DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY, FACULTY OF PHARMACY, UNIVERSITY OF KUFA, NAJAF, IRAQ.
3PHARMACEUTICS AND BIOPHARMACEUTICS, SCHOOL OF PHARMACY AND PHARMACEUTICAL SCIENCES, TRINITY COLLEGE DUBLIN, DUBLIN, IRELAND.
PubMed DOI

Abstract

OBJECTIVE: Aim: The current study aimed to determine the underlying mechanisms of protective effect of vildagliptin against sepsis induced liver injury. PATIENTS AND METHODS: Materials and methods: Male mice were randomly allocated to sham group, Cecal Ligation and Puncture group, Dimethyl sulfoxide group and vildagliptin group (20 mg/kg). Cecal Ligation and Puncture operation was established for…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.